11β-Hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes

Bibliography

• World Health Organization. Available from: http://www.who.int/diabetes/facts. [Last accessed July 2010]
   Google Scholar
• Roglic G, Unwin N, Bennett PH, The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005;28(9):2130-5
   PubMed Web of Science ®Google Scholar
• Sinha R, Fisch G, Teague B, Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 2002;346(11):802-10
   PubMed Web of Science ®Google Scholar
• Larsen PR, Kronenberg HM, Melmed S, Polonsky KS. Williams Textbook of Endocrinology. 10 edition. Saunders, Philadelphia, USA; 2003
   Google Scholar
• Becker KL, Bilezikian JP, Bremner WJ, Hung W. Principles and Practice of Endocrinology and Metabolism. 3 edition. Lippincott Williams and Wilkins, Philadelphia, USA; 2001
   Google Scholar
• Hammond GL. Molecular properties of corticosteroid binding globulin and the sex-steroid binding proteins. Endocr Rev 1990;11(1):65-79
   PubMed Web of Science ®Google Scholar
• Giguere V, Hollenberg SM, Rosenfeld MG, Evans RM. Functional domains of the human glucocorticoid receptor. Cell 1986;46(5):645-52
   PubMed Web of Science ®Google Scholar
• Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 1997;18(3):306-60
   PubMed Web of Science ®Google Scholar
• Pratt WB. The hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors. Proc Soc Exp Biol Med 1998;217(4):420-34
   PubMed Web of Science ®Google Scholar
• Stancato LF, Silverstein AM, Gitler C, Use of the thiol-specific derivatizing agent N-iodoacetyl-3-[125I]iodotyrosine to demonstrate conformational differences between the unbound and hsp90-bound glucocorticoid receptor hormone binding domain. J Biol Chem 1996;271(15):8831-6
   PubMed Web of Science ®Google Scholar
• Adcock IM. Molecular mechanisms of glucocorticosteroid actions. Pulm Pharmacol Ther 2000;13(3):115-26
   PubMed Web of Science ®Google Scholar
• Schaaf MJ, Cidlowski JA. Molecular mechanisms of glucocorticoid action and resistance. J Steroid Biochem Mol Biol 2002;83(1-5):37-48
   PubMed Web of Science ®Google Scholar
• Medh RD, Webb MS, Miller AL, Gene expression profile of human lymphoid CEM cells sensitive and resistant to glucocorticoid-evoked apoptosis. Genomics 2003;81(6):543-55
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336(15):1066-71
   PubMed Web of Science ®Google Scholar
• Croxtall JD, van Hal PT, Choudhury Q, Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells. Br J Pharmacol 2002;135(2):511-19
   PubMed Web of Science ®Google Scholar
• Croxtall JD, Choudhury Q, Flower RJ. Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. Br J Pharmacol 2000;130(2):289-98
   PubMed Web of Science ®Google Scholar
• Liu L, Wang YX, Zhou J, Rapid non-genomic inhibitory effects of glucocorticoids on human neutrophil degranulation. Inflamm Res 2005;54(1):37-41
   PubMed Web of Science ®Google Scholar
• Chen F, Watson CS, Gametchu B. Association of the glucocorticoid receptor alternatively-spliced transcript 1A with the presence of the high molecular weight membrane glucocorticoid receptor in mouse lymphoma cells. J Cell Biochem 1999;74(3):430-46
   PubMed Web of Science ®Google Scholar
• Gametchu B, Watson CS, Wu S. Use of receptor antibodies to demonstrate membrane glucocorticoid receptor in cells from human leukemic patients. FASEB J 1993;7(13):1283-92
   PubMed Web of Science ®Google Scholar
• Hafezi-Moghadam A, Simoncini T, Yang Z, Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med 2002;8(5):473-9
   PubMed Web of Science ®Google Scholar
• Whorwood CB, Mason JI, Ricketts ML, Detection of human 11 beta-hydroxysteroid dehydrogenase isoforms using reverse-transcriptase-polymerase chain reaction and localization of the type 2 isoform to renal collecting ducts. Mol Cell Endocrinol 1995;110(1-2):R7-12
   PubMed Web of Science ®Google Scholar
• Whorwood CB, Ricketts ML, Stewart PM. Epithelial cell localization of type 2 11 beta-hydroxysteroid dehydrogenase in rat and human colon. Endocrinology 1994;135(6):2533-41
   PubMed Web of Science ®Google Scholar
• White PC, Mune T, Rogerson FM, 11 beta-Hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess. Pediatr Res 1997;41(1):25-9
   PubMed Web of Science ®Google Scholar
• Ricketts ML, Verhaeg JM, Bujalska I, Immunohistochemical localization of type 1 11beta-hydroxysteroid dehydrogenase in human tissues. J Clin Endocrinol Metab 1998;83(4):1325-35
   PubMed Web of Science ®Google Scholar
• Jamieson PM, Chapman KE, Edwards CR, Seckl JR. 11 beta-hydroxysteroid dehydrogenase is an exclusive 11 beta- reductase in primary cultures of rat hepatocytes: effect of physicochemical and hormonal manipulations. Endocrinology 1995;136(11):4754-61
   PubMed Web of Science ®Google Scholar
• Morgan SA, Sherlock M, Gathercole LL, 11beta-hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes 2009;58(11):2506-15
   PubMed Web of Science ®Google Scholar
• Bujalska IJ, Walker EA, Hewison M, Stewart PM. A switch in dehydrogenase to reductase activity of 11 beta-hydroxysteroid dehydrogenase type 1 upon differentiation of human omental adipose stromal cells. J Clin Endocrinol Metab 2002;87(3):1205-10
   PubMed Web of Science ®Google Scholar
• Stewart PM, Murry BA, Mason JI. Human kidney 11 beta-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform. J Clin Endocrinol Metab 1994;79(2):480-4
   PubMed Web of Science ®Google Scholar
• Ozols J. Lumenal orientation and post-translational modifications of the liver microsomal 11 beta-hydroxysteroid dehydrogenase. J Biol Chem 1995;270(5):2305-12
   PubMed Web of Science ®Google Scholar
• Bujalska IJ, Draper N, Michailidou Z, Hexose-6-phosphate dehydrogenase confers oxo-reductase activity upon 11 beta-hydroxysteroid dehydrogenase type 1. J Mol Endocrinol 2005;34(3):675-84
   PubMed Web of Science ®Google Scholar
• Lavery GG, Walker EA, Draper N, Hexose-6-phosphate dehydrogenase knock-out mice lack 11 beta-hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation. J Biol Chem 2006;281(10):6546-51
   PubMed Web of Science ®Google Scholar
• Kotelevtsev Y, Holmes MC, Burchell A, 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 1997;94(26):14924-9
   PubMed Web of Science ®Google Scholar
• Morton NM, Paterson JM, Masuzaki H, Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004;53(4):931-8
   PubMed Web of Science ®Google Scholar
• Masuzaki H, Paterson J, Shinyama H, A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294(5549):2166-70
   PubMed Web of Science ®Google Scholar
• Masuzaki H, Yamamoto H, Kenyon CJ, Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 2003;112(1):83-90
   PubMed Web of Science ®Google Scholar
• Kershaw EE, Morton NM, Dhillon H, Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes 2005;54(4):1023-31
   PubMed Web of Science ®Google Scholar
• Paterson JM, Morton NM, Fievet C, Metabolic syndrome without obesity: hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA 2004;101(18):7088-93
   PubMed Web of Science ®Google Scholar
• Stewart PM, Boulton A, Kumar S, Cortisol metabolism in human obesity: impaired cortisone – cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 1999;84(3):1022-7
   PubMed Web of Science ®Google Scholar
• Valsamakis G, Anwar A, Tomlinson JW, 11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004;89(9):4755-61
   PubMed Web of Science ®Google Scholar
• Abdallah BM, Beck-Nielsen H, Gaster M. Increased expression of 11beta-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes. Eur J Clin Invest 2005;35(10):627-34
   PubMed Web of Science ®Google Scholar
• Whorwood CB, Donovan SJ, Flanagan D, Increased glucocorticoid receptor expression in human skeletal muscle cells may contribute to the pathogenesis of the metabolic syndrome. Diabetes 2002;51(4):1066-75
   PubMed Web of Science ®Google Scholar
• Engeli S, Bohnke J, Feldpausch M, Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss. Obes Res 2004;12(1):9-17
   PubMedGoogle Scholar
• Goedecke JH, Wake DJ, Levitt NS, Glucocorticoid metabolism within superficial subcutaneous rather than visceral adipose tissue is associated with features of the metabolic syndrome in South African women. Clin Endocrinol 2006;65(1):81-7
   PubMed Web of Science ®Google Scholar
• Kannisto K, Pietilainen KH, Ehrenborg E, Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J Clin Endocrinol Metab 2004;89(9):4414-21
   PubMed Web of Science ®Google Scholar
• Lindsay RS, Wake DJ, Nair S, Subcutaneous adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J Clin Endocrinol Metab 2003;88(6):2738-44
   PubMed Web of Science ®Google Scholar
• Paulmyer-Lacroix O, Boullu S, Oliver C, Expression of the mRNA coding for 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab 2002;87(6):2701-5
   PubMed Web of Science ®Google Scholar
• Rask E, Olsson T, Soderberg S, Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001;86(3):1418-21
   PubMed Web of Science ®Google Scholar
• Rask E, Walker BR, Soderberg S, Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 2002;87(7):3330-6
   PubMed Web of Science ®Google Scholar
• Sandeep TC, Andrew R, Homer NZ, Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes 2005;54(3):872-9
   PubMed Web of Science ®Google Scholar
• Monder C, Stewart PM, Lakshmi V, Licorice inhibits corticosteroid 11 beta-dehydrogenase of rat kidney and liver: in vivo and in vitro studies. Endocrinology 1989;125(2):1046-53
   PubMed Web of Science ®Google Scholar
• Schweizer RA, Atanasov AG, Frey BM, Odermatt A. A rapid screening assay for inhibitors of 11beta-hydroxysteroid dehydrogenases (11beta-HSD): flavanone selectively inhibits 11beta-HSD1 reductase activity. Mol Cell Endocrinol 2003;212(1-2):41-9
   PubMed Web of Science ®Google Scholar
• Diederich S, Grossmann C, Hanke B, In the search for specific inhibitors of human 11beta-hydroxysteroid-dehydrogenases (11beta-HSDs): chenodeoxycholic acid selectively inhibits 11beta-HSD-I. Eur J Endocrinol 2000;142(2):200-7
   PubMed Web of Science ®Google Scholar
• Latif SA, Pardo HA, Hardy MP, Morris DJ. Endogenous selective inhibitors of 11beta-hydroxysteroid dehydrogenase isoforms 1 and 2 of adrenal origin. Mol Cell Endocrinol 2005;243(1-2):43-50
   PubMed Web of Science ®Google Scholar
• Walker BR, Connacher AA, Lindsay RM, Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab 1995;80(11):3155-9
   PubMed Web of Science ®Google Scholar
• Andrews RC, Rooyackers O, Walker BR. Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 2003;88(1):285-91
   PubMed Web of Science ®Google Scholar
• Barf T, Vallgarda J, Emond R, Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1. J Med Chem 2002;45(18):3813-5
   PubMed Web of Science ®Google Scholar
• Alberts P, Engblom L, Edling N, Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002;45(11):1528-32
   PubMed Web of Science ®Google Scholar
• Alberts P, Nilsson C, Selen G, Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 2003;144(11):4755-62
   PubMed Web of Science ®Google Scholar
• Sundbom M, Kaiser C, Bjorkstrand E, Inhibition of 11betaHSD1 with the S-phenylethylaminothiazolone BVT116429 increases adiponectin concentrations and improves glucose homeostasis in diabetic KKAy mice. BMC Pharmacol 2008;8:3
   PubMedGoogle Scholar
• Hermanowski-Vosatka A, Balkovec JM, Cheng K, 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 2005;202(4):517-27
   PubMed Web of Science ®Google Scholar
• Berthiaume M, Laplante M, Festuccia W, Depot-specific modulation of rat intraabdominal adipose tissue lipid metabolism by pharmacological inhibition of 11beta-hydroxysteroid dehydrogenase type 1. Endocrinology 2007;148(5):2391-7
   PubMed Web of Science ®Google Scholar
• Berthiaume M, Laplante M, Festuccia WT, 11beta-HSD1 inhibition improves triglyceridemia through reduced liver VLDL secretion and partitions lipids toward oxidative tissues. Am J Physiol Endocrinol Metab 2007;293(4):E1045-52
   PubMed Web of Science ®Google Scholar
• Berthiaume M, Laplante M, Festuccia WT, Preliminary report: pharmacologic 11beta-hydroxysteroid dehydrogenase type 1 inhibition increases hepatic fat oxidation in vivo and expression of related genes in rats fed an obesogenic diet. Metabolism 2010;59(1):114-17
   PubMed Web of Science ®Google Scholar
• Berthiaume M, Laplante M, Festuccia WT, Additive action of 11beta-HSD1 inhibition and PPAR-gamma agonism on hepatic steatosis and triglyceridemia in diet-induced obese rats. Int J Obes (Lond) 2009;33(5):601-4
   PubMed Web of Science ®Google Scholar
• Lloyd DJ, Helmering J, Cordover D, Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis. Diabetes Obes Metab 2009;11(7):688-99
   PubMed Web of Science ®Google Scholar
• Bhat BG, Hosea N, Fanjul A, Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4′-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11-hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys. J Pharmacol Exp Ther 2008;324(1):299-305
   PubMed Web of Science ®Google Scholar
• Courtney R, Stewart PM, Toh M, Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor. J Clin Endocrinol Metab 2008;93(2):550-6
   PubMed Web of Science ®Google Scholar
• Hawkins M, Hunter D, Kishore P, INCB013739, a Selective inhibitor of 11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1), improves insulin sensitivity and lower plasma cholesterol over 28 days in patients with type 2 diabetes mellitus [abstract 344-OR]. 68th Scientific session of the American Diabetes Association; 6 – 10 June 2008; San Francisco
   Google Scholar
• Rosenstock J, Banarer S, Fonseca VA, The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 2010;33(7):1516-22
   PubMed Web of Science ®Google Scholar
• Lavery GG, Walker EA, Tiganescu A, Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency. J Clin Endocrinol Metab 2008;93(10):3827-32
   PubMed Web of Science ®Google Scholar
• Densmore VS, Morton NM, Mullins JJ, Seckl JR. 11 beta-hydroxysteroid dehydrogenase type 1 induction in the arcuate nucleus by high-fat feeding: a novel constraint to hyperphagia? Endocrinology 2006;147(9):4486-95
   PubMed Web of Science ®Google Scholar
• Veniant MM, Hale C, Komorowski R, Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice. Diabetes Obes Metab 2009;11(2):109-17
   PubMed Web of Science ®Google Scholar
• Shackleton CH, Hughes BA, Lavery GG, The corticosteroid metabolic profile of the mouse. Steroids 2008;73(11):1066-76
   PubMed Web of Science ®Google Scholar
• Chapman KE, Coutinho AE, Gray M, The role and regulation of 11beta-hydroxysteroid dehydrogenase type 1 in the inflammatory response. Mol Cell Endocrinol 2009;301(1-2):123-31
   PubMed Web of Science ®Google Scholar